These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26076014)

  • 1. Where and When To Inject Low Molecular Weight Heparin in Hemodiafiltration? A Cross Over Randomised Trial.
    Dhondt A; Pauwels R; Devreese K; Eloot S; Glorieux G; Vanholder R
    PLoS One; 2015; 10(6):e0128634. PubMed ID: 26076014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis.
    Stefoni S; Cianciolo G; Donati G; Colì L; La Manna G; Raimondi C; Dalmastri V; Orlandi V; D'Addio F
    Nephron; 2002; 92(3):589-600. PubMed ID: 12372942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose effect relationship of reviparin in chronic hemodialysis: a crossover study versus nadroparin.
    Reach I; Luong N; Chastang C; Chakroun M; Mirshahi S; Mirshahi MC; Soria J; Desmichels D; Baumelou A
    Artif Organs; 2001 Jul; 25(7):591-5. PubMed ID: 11493282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
    Hainer JW; Sherrard DJ; Swan SK; Barrett JS; Assaid CA; Fossler MJ; Cox DS; Williams RM; Pittenger AL; Stephenson CA; Hua TA
    Am J Kidney Dis; 2002 Sep; 40(3):531-8. PubMed ID: 12200805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of coagulation and anti-Xa factor when using a heparin-coated AN69ST® dialyser.
    Sánchez-Canel JJ; Pons-Prades R; Salvetti ML; Seores A; Vázquez M; Pérez-Alba A; Tamarit E; Calvo-Gordo C; Villatoro J
    Nefrologia; 2012; 32(5):605-12. PubMed ID: 23013946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.
    Barrett JS; Hainer JW; Kornhauser DM; Gaskill JL; Hua TA; Sprogel P; Johansen K; van Lier JJ; Knebel W; Pieniaszek HJ
    Thromb Res; 2001 Feb; 101(4):243-54. PubMed ID: 11248285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of the pharmacokinetic profiles of two LMWHs--bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa)--administered subcutaneously to healthy male volunteers.
    Depasse F; González de Suso MJ; Lagoutte I; Fontcuberta J; Borrell M; Samama MM
    Thromb Res; 2003 Jan; 109(2-3):109-17. PubMed ID: 12706639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bedside monitoring of anticoagulation in chronic haemodialysis patients treated with tinzaparin.
    Pauwels R; Devreese K; Van Biesen W; Eloot S; Glorieux G; Vanholder R; Dhondt A
    Nephrol Dial Transplant; 2014 May; 29(5):1092-6. PubMed ID: 24366900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two low-molecular weight heparins (LMWHs), tinzaparin and bemiparin, during hemodialysis.
    Christidou FN; Frangia TK; Bamichas GI; Gionanlis LC; Natse TA; Georgoulis IE; Sombolos KI
    Int J Clin Pharmacol Ther; 2005 Jul; 43(7):335-8. PubMed ID: 16035376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the anticoagulant effect of low-molecular-weight heparins based on the anti-Xa level during haemodialysis.
    Tao M; Zheng D; Liang X; Ye M; Liu Y; Li Y; Shen H; He Q
    Nephrology (Carlton); 2020 Sep; 25(9):723-729. PubMed ID: 31999031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center.
    Lord H; Jean N; Dumont M; Kassis J; Leblanc M
    Am J Nephrol; 2002; 22(1):58-66. PubMed ID: 11919404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
    Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
    Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers.
    Fossler MJ; Barrett JS; Hainer JW; Riddle JG; Ostergaard P; van der Elst E; Sprogel P
    Am J Health Syst Pharm; 2001 Sep; 58(17):1614-21. PubMed ID: 11556655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanded hemodialysis: Is anticoagulation of the dialysis circuit different from online hemodiafiltration and high-flux hemodialysis?
    Santos A; Macías N; Vega A; Abad S; Linares T; Aragoncillo I; Cruzado L; Pascual C; Goicoechea M; López-Gómez JM
    Ther Apher Dial; 2022 Feb; 26(1):147-153. PubMed ID: 33890717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation with dalteparin and nadroparin in nocturnal haemodialysis.
    Verhave G; Weijmer MC; van Jaarsveld BC
    Neth J Med; 2015 Jul; 73(6):270-5. PubMed ID: 26228191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin-grafted dialysis membrane allows minimal systemic anticoagulation in regular hemodialysis patients: a prospective proof-of-concept study.
    Kessler M; Gangemi C; Gutierrez Martones A; Lacombe JL; Krier-Coudert MJ; Galland R; Kielstein JT; Moureau F; Loughraieb N
    Hemodial Int; 2013 Apr; 17(2):282-93. PubMed ID: 22925178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profile of low molecular weight tinzaparin sodium for anticoagulation during hemodialysis.
    Al-Saran KA; Sabry A; Taha M; Ghafour MA; Al Fawzan F
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):43-9. PubMed ID: 20061691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose titration study of tinzaparin, a low molecular weight heparin, in patients on chronic hemodialysis.
    Egfjord M; Rosenlund L; Hedegaard B; Buchardt HL; Stengel C; Gardar P; Andersen L; Andersen L
    Artif Organs; 1998 Aug; 22(8):633-7. PubMed ID: 9702313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular adhesion protein-1 in hemodialysis and hemodiafiltration patients: effect of single hemodialysis session on its level in regard to type of anticoagulant.
    Malyszko J; Koc-Zorawska E; Kozminski P; Malyszko JS
    Int Urol Nephrol; 2017 May; 49(5):875-879. PubMed ID: 28044236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dalteparin dosing in high-flux haemodialysis and haemodiafiltration.
    Sridharan S; Berdeprado J; Sivalingam M; Farrington K
    Nephron Clin Pract; 2012; 122(1-2):53-7. PubMed ID: 23548465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.